David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.
Last updated: 2026-11-19 02:40:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $369.89, with a market capitalization of $9.69B and a P/E ratio of 9.42. Over the past 52 weeks, its price has ranged from $236.73 to $396.23. This page covers its latest market performance, valuation, price trends and company information.
$9.69B | |
$358.00 | |
$370.60 | |
$358.00 | |
$358.19 | |
221.45K | |
255.63K | |
9.42 | |
$396.23 | |
$236.73 | |
-- | |
2026-09-30 |
Bio-Rad Laboratories, Inc. (BIO) last closed at $369.89 as of 2026-11-19 00:33:00, up 3.34% ($11.98) from the previous close of $358.19.
During the latest regular trading session, BIO traded between $358.00 and $370.60, with a volume of 221.45K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO) moved from $388.31 to $369.89, representing a decline of 4.74% ($18.42).
The stock traded between $356.50 and $394.73 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 254.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.5%
BIO is currently trading at $369.89, placing it 83.5% of the way from its 52-week low of $236.73 to its 52-week high of $396.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7,450 |
| Exchange | NYSE |
| Company Website |
Latest news related to Bio-Rad Laboratories, Inc. and BIO stock.
DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BIO shares and USD.
BIO Shares to USD
1.00 BIO shares = 369.886 USD
Calculations are estimates based on the latest available price and are for reference only.